| Compound Information | SONAR Target prediction | | Name: | CYCLOSPORINE | | Unique Identifier: | SPE01502202 | | MolClass: | Checkout models in ver1.5 and ver1.0 | | Molecular Formula: | C62H111N11O12 | | Molecular Weight: | 1090.73 g/mol | | X log p: | 4.12 (online calculus) | | Lipinksi Failures | 3 | | TPSA | | | Hydrogen Bond Donor Count: | 5 | | Hydrogen Bond Acceptors Count: | 12 | | Rotatable Bond Count: | 12 | | Canonical Smiles: | CC=CCC(C)C(O)C1C(=O)NC(CC)C(=O)N(C)CC(=O)N(C)C(CC(C)C)C(=O)NC(C(C)C)C( =O)N(C)C(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(CC(C) C)C(=O)N(C)C(C(C)C)C(=O)N1(C) | | Class: | macrolide | | Source: | Tolypocladium inflatum | | Reference: | Helv Chim Acta 60: 1568 (1977) | | Therapeutics: | immunosuppressant | | Generic_name: | Cyclosporine | | Chemical_iupac_name: | Cyclosporine | | Drug_type: | Approved Drug | | Pharmgkb_id: | PA449167 | | Drugbank_id: | BIOD00003 | | Logp: | 4.293 | | Cas_registry_number: | 59865-13-3 | | Drug_category: | Immunmodulatory Agents; Immunosupressants | | Indication: | For treatment of transplant rejection, rheumatoid arthritis, severe psoriasis | | Pharmacology: | Used in immunosuppression for prophylactic treatment of organ transplants, cyclosporine exerts specific and reversible inhibition of immunocompetent lymphocytes in the G0-or G1-phase of the cell cycle. T-lymphocytes are preferentially inhibited. The T1-helper cell is the main target, although the T1-suppressor cell may also be suppressed. Sandimmune (cyclosporine) also inhibits lymphokine production and release including interleukin-2. | | Mechanism_of_action: | Cyclosporine binds to cyclophillin. The complex then inhibits calcineurin which is normally responsible for activating transcription of interleukin 2. Cyclosporine also inhibits lymphokine production and ineterluekin relase. | | Organisms_affected: | Humans and other mammals |
| Species: |
4932 |
| Condition: |
TFP1 |
| Replicates: |
2 |
| Raw OD Value: r im |
0.2569±0.0217082 |
| Normalized OD Score: sc h |
0.3577±0.0305317 |
| Z-Score: |
-26.8772±1.65797 |
| p-Value: |
0 |
| Z-Factor: |
-0.0589691 |
| Fitness Defect: |
INF |
| Bioactivity Statement: |
Active |
| Experimental Conditions | | | Library: | Spectrum | | Plate Number and Position: | 24|A5 | | Drug Concentration: | 50.00 nM | | OD Absorbance: | 600 nm | | Robot Temperature: | 26.30 Celcius | | Date: | 2007-08-31 YYYY-MM-DD | | Plate CH Control (+): | 0.04105±0.00024 | | Plate DMSO Control (-): | 0.6859999999999999±0.12654 | | Plate Z-Factor: | 0.3843 |
| png ps pdf |
| 2909 |
30-ethyl-33-(1-hydroxy-2-methyl-hex-4-enyl)-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-meth ylpropyl)-3,21-dipropan-2-yl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20 ,23,26,29,32-undecone |
| 171409 |
(3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(1R,2R)-1-hydroxy-2-methyl-hex-4-enyl]-1,4,7,10,12,1 5,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-dipropan-2-yl-1,4,7,10,13,16,19,22,25,28,3 1-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone |
| 5280754 |
30-ethyl-33-[(E)-1-hydroxy-2-methyl-hex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2- methylpropyl)-3,21-dipropan-2-yl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,1 7,20,23,26,29,32-undecone |
| 5284373 |
(3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methyl-hex-4-enyl]-1,4,7,10,12 ,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-dipropan-2-yl-1,4,7,10,13,16,19,22,25,28 ,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone |
| 5287812 |
(3S,6S,9S,12R,15S,18S,21S,24S,27R,30S,33S)-30-ethyl-27-(hydroxymethyl)-33-[(E,1R,2R)-1-hydroxy-2-methyl- hex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-dipropan-2-yl-1,4 ,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone |
| 5287814 |
(3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methyl-hex-4-enyl]-1,4,7,10,12 ,15,19,25,28-nonamethyl-24-[(2R)-2-methylbutyl]-6,9,18-tris(2-methylpropyl)-3,21-dipropan-2-yl-1,4,7,10, 13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone |
| internal high similarity DBLink | Rows returned: 1 | |
| nonactive | Cluster 1190 | Additional Members: 4 | Rows returned: 2 | |
|